Sentences with phrase «of diagnostic assays»

Dr. Manak has helped set up and direct various collaborative programs with developers of infectious disease tests including Hologic, Roche, Bio-Rad, SpotOn and SeraCare as well as partnerships with government agencies for evaluation of diagnostic assays and devices.

It will be extremely important to identify and characterize those viruses as quickly as possible — to get a head start on the development of diagnostic assays for surveillance and drugs, or vaccines for treatment — before they have a chance to really spread.»

The Institute hopes to eventually obtain viral isolates for medical countermeasure development and receive data on the performance of the diagnostic assays.

The scientists next plan to evaluate the precise roles of the five genes and to validate the accuracy of their diagnostic assay in a prospective clinical study.

Not exact matches

NEW YORK (360Dx)-- Biotech firm Berg continued its push into cancer diagnostics with the presentation of several posters earlier this month at the annual meeting of the American Association for Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperplasia.

Fully implemented targeted sequencing - based assays in routine diagnostic pathology laboratories are currently lacking in lymphoid cancer care,» explained Christian Steidl, MD, Senior Scientist at the BC Cancer and Associate Professor in the Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

In 2011, she joined the institution's molecular diagnostics laboratory where she has been developing translational next generation sequencing assays and bioinformatics workflows for the Molecular Tumor Profiling Lab of the Yale Cancer Center.

So we wanted to elucidate the molecular basis of that resistance in the population and design a field applicable diagnostic assay for its monitoring.»

The prospective cohort study met both its primary endpoints: to determine the association between troponin T levels measured by a high - sensitivity troponin T assay and the risk of death within a month of non-cardiac surgery, and to identify diagnostic criteria for myocardial injury after non-cardiac surgery that defines whether or not serious injury to the heart has occurred.

Use of genomics to design a diagnostic assay to discriminate between Streptococcus pneumoniae and Streptococcus pseudopneumoniae — Matthew A. Croxen — Microbial Genomics

The Showe Laboratory will be performing the optimization and validation of the prototype glioblastoma diagnostic test, transferring the assay to a more versatile technology platform that is better suited for clinical applications.

• Customized mutation screening assays Biotage, the manufacturing company of the genetic analyzer PyroMark ID, offers in its database more than 1,000 customized assays for routine clinical screening diagnostics.

Within our lab we exploit the unique DNA methylation profiles of brain cells to create molecular diagnostic assays capable of detecting peripheral neurological cell free DNA.

This gene is identified by an investigational FLT3 Mutation Assay companion diagnostic a specific lab test of their blood or bone marrow, which is used to see if they have a mutation of the FLT3 gene.

Whole swathes of diagnostic tests may eventually be replaced with a single assay - sequencing - as we reach the «sequencing singularity».

Functional understanding of candidate proteins is vital to assay development, compound design, and diagnostic / prognostic utilizations.

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

DENVER — A pre-competitive consortia of pharmaceutical, diagnostic companies and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the «BLUEPRINT PD - L1 IHC ASSAY COMPARISON PROJECT» at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.

This assay will be a useful tool for differential Zika fever diagnostics in a situation where number of other disease like malaria, dengue, chikungunya co-circulate and are clinically indistinguishable.

Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED - 2 PCR Assay.

Four of the mAbs, 2T5C9, 2G9C, T1F11, and TB2H7, demonstrated diagnostic potential in enzyme - linked immunosorbent assays (ELISA) by their low to sub-nanomolar cross-reactivity with recombinant wild - type (WT) and mutant TTR aggregates and lack of binding to native TTR or amyloid fibrils formed by other peptides or proteins.

We provide a full - range of standardized CE - marked in vitro diagnostic products for hematology - oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

As a reagent manufacturer, we offer a comprehensive selection of gel, capillary, and next - generation sequencing PCR assays for gene rearrangement, chromosome translocation, and gene mutation detection as analyte specific reagents (United States), research use only, or CE - marked in vitro diagnostics to laboratories (outside of North America).

The LymphoTrack ® Dx TRB Assay for the Illumina MiSeq ® is an in vitro diagnostic product intended for next - generation sequencing (NGS) based determination of the frequency distribution of TRB gene rearrangements in patients suspected with having lymphoproliferative disease.

Dr. Shendure's research group in Seattle pioneered exome sequencing and its earliest applications to gene discovery for Mendelian disorders (e.g. Miller and Kabuki syndrome) and autism; cell - free DNA diagnostics for cancer and reproductive medicine; massively parallel reporter assays and saturation genome editing; whole organism lineage tracing; and massively parallel molecular profiling of single cells.

Esko is collaborating with Zacharon Pharmaceuticals, a San Diego - based biotechnology company, to develop a commercial diagnostic assay for differentiating forms of MPS from urine and blood samples, a screening test for newborns and a tool for measuring the biochemical response of MPS patients to existing and novel therapies.

CLINIQA, ISO 13485:2003 / 9001:2008 certified, is a clinical diagnostics manufacturer of diagnostic test kits / assays, quality controls, calibrators, linearity calibration verifiers, reagents, proficiency testing materials as well as biological raw materials used worldwide.

It is a paper based vertical flow microarray assay that could find use in future point of care affinity proteomic applications, for instance in the fields of autoimmunity, allergy, infection or cancer diagnostics.

SEngine Precision Medicine, instead, is pursuing an innovative approach for the development of novel targets and drugs for cancer therapy by using primary patient organoids initially derived for our diagnostic assay.

SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

With ~ 81 % of the human proteome on a single slide, ImmuneProfiler represents a more comprehensive and high - throughput alternative to other assay platforms for the development of predictive early diagnostic tests.

In order to develop field - applicable diagnostics for Vgsc CN, and as a prelude to investigating the possible association of CN with insecticide resistance, three assays were compared for their accuracy in CN estimation in this species.

Prior to Joining MHRP, Dr. Manak was the Chief Scientist of SeraCare Life Sciences Inc., where he led the development of seroconversion and performance panels widely used by the in vitro diagnostics community for development, evaluation and validation of in vitro diagnostic assays used in screening and monitoring of infectious diseases.

For eight of these 11 events, mosaicism was observed in saliva but not blood, suggesting that assaying blood alone would miss a large fraction, possibly > 50 %, of mosaic diagnostic chromosomal rearrangements.

Dr. Manak has extensive expertise in development and validation of in - house and commercial assays for HIV and related infectious diseases and their use in diagnostic, epidemiological, vaccine and therapeutic programs.

TRIB also acquired Fiomi Diagnostics, a Swedish company at an advanced stage in developing a panel of point - of - care cardiac marker assays, particularly for Troponin I. $ 60 mio «s already been spent on the technology, and it offers TRIB a slice of the $ 900 mio Cardiac POC diagnostics market, which is growing 14 % pa.

To create a noninvasive diagnostic test, we developed and validated a novel PCR assay to detect N. cati DNA in fecal samples of bobcats (Lynx rufus) and used this assay to investigate a recent outbreak of mange in northern California, United States.

«Using a rapid assay that detects a target in the gene that encodes the neuraminidase protein on the surface of the virus, we have confirmed the subtype to be N2,» says Kathy Toohey - Kurth, clinical professor and virology section head at the diagnostic lab.

«Henry Schein's companion animal health distribution business is the largest in North America and our customers consistently rely on us for a comprehensive line of products and services, including a full range of veterinary diagnostics products such as instruments, consumables and rapid assays,» said Lonnie Shoff, the Chief Executive Officer of Henry Schein's Global Animal Health and Strategic Partnership Group.

The other type of test, indirect immunofluorescent antibody assay (IFA), must be sent to a diagnostic lab and only detects secondary viremia.

Prospective Diagnostic Accuracy Evaluation and Clinical Utilization of a Modified Assay for Platelet Associated Immunoglobulin in Thrombocytopenic and Non-Thrombocytopenic Dogs.

The lower diagnostic specificity of this qPCR assay may be the result of the lower limit of detection of this assay compared with the gold standard rather than the result of detection of true false - positives.

Compared with the gold standard conventional pan-adenovirus PCR / sequencing assay, diagnostic sensitivity and specificity of 100 % and 88.2 % were found, respectively.

Veterinary professionals are advised that diagnostic testing of samples from sick pets can be done using a broadly targeted Influenza A matrix reverse transciptase - polymerase chain reaction assay (Rt - PCR).

Identification of Borrelia burgdorferi OspC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.

Represented Becton, Dickinson and Company in a patent infringement suit brought by Gen - Probe involving methods of automating nucleic acid diagnostic assays and related consumable products.

Typically, companies in the pharmaceutical and biotechnology industries file patents protecting small molecules, biologics (an antibody, peptide sequence, etc), methods of treatment or unique (diagnostic) assays (for detecting and / or treating disease).

Executed and documented experimental test designs for donor screening and diagnostic assays, feasibility of a new donor screening system